AlloVir (Nasdaq:ALVR) - Aandelenkoers, Nieuws & Analyse

ALVR Overzicht aandelen

Allovir, Inc., een celtherapiebedrijf in een klinische fase, houdt zich bezig met onderzoek naar en ontwikkeling van allogene, kant-en-klare multivirusspecifieke T-celtherapieën (VST) voor de preventie en behandeling van verwoestende, virusgebonden ziekten.

Over het bedrijf

ALVR fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

AlloVir, Inc. Concurrenten

BioAtla

NasdaqGM:BCAB

US$99.6m

Lirum Therapeutics

NasdaqCM:LRTX

US$102.0m

CervoMed

NasdaqCM:CRVO

US$106.0m

Adicet Bio

NasdaqGM:ACET

US$107.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor AlloVir
Historische aandelenkoersen
Huidige aandelenkoers	US$0.98
52 Week Hoogtepunt	US$2.49
52 Week Laag	US$0.58
Bèta	0.78
11 maand verandering	23.83%
3 maanden verandering	35.29%
1 Jaar Verandering	-30.14%
33 jaar verandering	-95.83%
5 jaar verandering	n/a
Verandering sinds IPO	-96.13%

Recent nieuws en updates

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Oct 29

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

Jul 13

Recent updates

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Mar 21

AlloVir: A Comparative Study Of Its Manufacturing Process

Feb 07

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate

Nov 02

AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues

Oct 02

AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 06

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Jul 01

AlloVir EPS misses by $0.08

May 06

AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans

Apr 01

This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)

Feb 07

Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?

Jan 08

FDA clears AlloVir's ALVR106 application in respiratory viruses

Dec 17

Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data

Dec 07

We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth

Dec 04

AlloVir EPS misses by $0.28

Nov 10

Rendement voor aandeelhouders

	ALVR	US Biotechs	US Markt
7D	5.5%	4.3%	5.1%
1Y	-30.1%	29.2%	37.7%

Rendement versus industrie: ALVR presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 29.2 % opleverde.

Rendement versus markt: ALVR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 37.7 % opleverde.

Prijsvolatiliteit

Is ALVR's price volatile compared to industry and market?
ALVR volatility
ALVR Average Weekly Movement	6.7%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: ALVR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ALVR is het afgelopen jaar gedaald van 12% naar 7%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2013	8	Diana Brainard	www.allovir.com

Allovir, Inc., een celtherapiebedrijf in een klinische fase, houdt zich bezig met onderzoek naar en ontwikkeling van allogene, kant-en-klare multivirusspecifieke T celtherapieën (VST) voor de preventie en behandeling van verwoestende virusziekten. Het belangrijkste product van het bedrijf is posoleucel, een allogene, off-the-shelf VST-therapie voor de behandeling van BK-virus, cytomegalovirus, adenovirus, Epstein-Barr-virus, humaan herpesvirus 6 en JC-virus. Tot de preklinische en klinische productkandidaten behoren ALVR106 voor het respiratoir syncytieel virus, influenza, parainfluenza virus en humaan metapneumovirus; ALVR109 voor de behandeling van SARS-CoV-2 en COVID-19; ALVR107 voor de behandeling van hepatitis B; en ALVR108.

AlloVir, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van AlloVir zich tot de beurswaarde?
ALVR fundamentele statistieken
Marktkapitalisatie	US$115.26m
Inkomsten(TTM)	-US$140.34m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.8x

Koers/Winstverhouding

Is ALVR overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ALVR resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$140.34m
Inkomsten	-US$140.34m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.23
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ALVR op de lange termijn?

Bekijk historische prestaties en vergelijking

ALVR Overzicht aandelen

Beloningen

Risicoanalyse

AlloVir, Inc. Concurrenten

NasdaqGM:BCAB

US$99.6m

NasdaqCM:LRTX

US$102.0m

NasdaqCM:CRVO

US$106.0m

NasdaqGM:ACET

US$107.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Recent updates

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely

Price target decreased by 20% to US$0.80

Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely

New major risk - Financial position

AlloVir, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Levi & Korsinsky, LLP Notifies Investors in Allovir, Inc. of a Class Action Securities Lawsuit

We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully

Robbins LLP Announces Class Action File Against AlloVir, Inc

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of a Class Action Against AlloVir, Inc. and Certain Officers

Price target decreased by 71% to US$5.63

AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation

New major risk - Share price stability

AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress

Allovir Announces Appointment of Cintia Piccina as Chief Commercial Officer

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target decreased by 7.6% to US$21.25

AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia

Price target decreased by 13% to US$23.00

CEO & Director notifies of intention to sell stock

AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study

Consultant notifies of intention to sell stock

Allovir, Inc. Announces the Resignation of Jeroen Van Beek as Executive Vice President and Chief Commercial Officer, Effective November 23, 2022

General Counsel & Secretary notifies of intention to sell stock

Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?

AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board notifies of intention to sell stock

Chief Accounting Officer recently sold US$99k worth of stock

Executive Chairman of the Board recently sold US$2.9m worth of stock

Chief Commercial Officer recently sold US$129k worth of stock

Price target decreased to US$27.50

AlloVir GAAP EPS of $0.69 beats by $1.42

AlloVir stock surges on $126.6M securities offering

Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?

AlloVir, Inc.(NasdaqGS:ALVR) dropped from Russell 2000 Growth Index

AlloVir, Inc. Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

Chief Commercial Officer recently sold US$67k worth of stock

Price target decreased to US$32.00

FDA Grants Regenerative Medicine Advanced Therapy to Allovir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

AlloVir, Inc., Annual General Meeting, May 17, 2022

AlloVir Announces Appointment of Shawn Tomasello to its Board of Directors

Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation

Chief Commercial Officer recently sold US$128k worth of stock

AlloVir: A Comparative Study Of Its Manufacturing Process

Price target decreased to US$38.75

Insider notifies of intention to sell stock

President recently sold US$56k worth of stock

AlloVir, Inc. Announces U.S. Food and Drug Administration Grant Lead Multi-Virus Specific T Cell (VST) Therapy, Posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Adenovirus (AdV) Infection

Price target decreased to US$42.75

AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting

Chief Commercial Officer recently sold US$321k worth of stock

Chief Scientific Officer notifies of intention to sell stock

We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate